<b>Background:</b> Sodium/glucose cotransporter-2 inhibitors (SGLT2is), such as dapagliflozin and empagliflozin, are currently a standard therapy for heart failure (HF) patients. The gene discussed is SLC5A2; the disease is hydrops fetalis.